1,303 patents currently held
52 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
110
Ending by 2030
Dec 2026
Next term end
604
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2031 · High confidence
Also notable
Ends Jun 2027 · High confidence
Also notable
Ends Jan 2032 · High confidence
Common Light Chain Mouse
US 10,143,186
Cited by 174 later US patents, top 1% of utility patents granted in 2018 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
VEGF Antagonist Formulations Suitable for Intravitreal Administration
US 11,066,458
Cited by 59 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2027. A terminal disclaimer caps this term to an earlier patent's.
Human Lambda Light Chain Mice
US 9,012,717
Cited by 129 later US patents, top 5% of utility patents granted in 2015 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 17 fees due Dec 2 to 30, 2026 · next Dec 2
- 19 fees due Jan 4 to 28, 2027 · next Jan 4
- 26 fees due Feb 1 to 28, 2027 · next Feb 1
- 23 fees due Mar 1 to 26, 2027 · next Mar 1
- 32 fees due Apr 1 to 30, 2027 · next Apr 1
- 23 fees due May 3 to 28, 2027 · next May 3
- 27 fees due Jun 3 to 30, 2027 · next Jun 3
- 25 fees due Jul 5 to 30, 2027 · next Jul 5
- 24 fees due Aug 4 to 27, 2027 · next Aug 4
- 18 fees due Sep 1 to 26, 2027 · next Sep 1
- 32 fees due Oct 2 to 30, 2027 · next Oct 2
- 9 fees due Nov 5 to 14, 2027 · next Nov 5
Recent changes
- Oct 21Assignment recorded on 1 record: Bansal, Ashish and 4 others to Regeneron Pharmaceuticals, Inc. Recorded Oct 21, 2026, executed Jul 9, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76454, frame 104.
- Oct 21Assignment recorded on 3 records: Bak, Hanne and 6 others to Regeneron Pharmaceuticals, Inc. Recorded Oct 21, 2026, executed Nov 12, 2015. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76456, frame 598.
- 43 of the patents on this record were granted since Aug 20, 2026
- 4 terms have ended since Aug 20, 2026
What they patent
The 5 largest of its 604 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Use of a VEGF Antagonist to Treat Angiogenic Eye Disorders | 13 in force | to May 2032 |
| Human Lambda Light Chain Mice | 13 in force | to Jan 2032 |
| VEGF Antagonist Formulations Suitable for Intravitreal Administration | 12 in force | to Jul 2027 |
| Anti-VEGF Protein Compositions and Methods for Producing the Same | 11 in force | to Aug 2040 |
| Adam6 Mice | 11 in force | to Apr 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,531,172 | Methods of Treating Diseases with a VEGF Antagonist In force · High confidence | In force | High confidence | |
| US 7,732,167 | Interferon-Alpha/Beta Binding Fusion Proteins and Therapeutic Uses Thereof In force · High confidence | In force | High confidence | |
| US 7,608,430 | Interferon-Gamma Antagonists and Therapeutic Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,080,248 | Method of Treating Rheumatoid Arthritis with an IL-6R Antibody In force · High confidence | In force | High confidence | |
| US 8,183,014 | High Affinity Antibodies to Human IL-6 Receptor In force · High confidence | In force | High confidence | |
| US 8,192,741 | Method of Treating Rheumatoid Arthritis with an ANTI-IL-6R Antibody In force · High confidence | In force | High confidence | |
| US 8,568,721 | Method of Treating Rheumatoid Arthritis with an Anti-IL-6R Antibody In force · High confidence | In force | High confidence | |
| US 9,308,256 | Method of Treating Rheumatoid Arthritis With An Anti-IL-6R Antibody In force · Medium confidence | In force | Medium confidence | |
| US 9,884,916 | High Affinity Antibodies to Human IL-6 Receptor In force · Medium confidence | In force | Medium confidence | |
| US 10,584,173 | Nucleic Acids Encoding High Affinity Antibodies to Human IL-6 Receptor In force · High confidence | In force | High confidence |
Also on record, not counted in the 1,303: 52 patents in force now held by others · 151 patents ended · 838 applications pending · 436 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.